REINACH, Switzerland, November 27 /PRNewswire-FirstCall/ -- Arpida announced today that it is refocusing all projects and priorities around the key strategic asset Iclaprim. The company says this is to be seen as a consequence of the negative recommendation of the U.S. Food and Drug Administration (FDA) advisory board on 20 November 2008 regarding the approval of Iclaprim in the U.S.
In the context of the FDA advisory board's recommendation the Arpida board intends to put the company back on a firm footing through cutting costs considerably. To achieve this, the company views the reduction of the workforce by up to 60 employees as inevitable. A consultation process with all employees has been initiated and will lead to decisions by the Board of Directors which will be communicated on 16 December 2008. Board and Management sincerely regret this measure and would like to point out that the company will endeavour to fully assume its social responsibilities. Contact with public authorities on this issue has been established and a social plan will be presented in time.
Arpida will now thoroughly analyse the situation with external experts to determine the future development of Iclaprim. Basis for this analysis will be the full FDA response to the Iclaprim dossier and the publication of the phase II oral step down therapy trial.
"We were very surprised by this very clear negative ruling by the FDA
advisory board", CEO Jurgen Raths said. "In particular we are very upset by
the steps we are forced to take in regards to our staff. The advisory board's
recommendation has come totally unexpected, because we are still convinced
that Iclaprim offers a valuable therapeutic asset for the treatment of
complicated skin and skin structure infections (cSSSI), especially where MRSA
(resistant bacteria called methicillin-resistant staphylococcus aureus) are
involved. We will use the FDA's feedback as well as furthe
|SOURCE Arpida Ltd.|
Copyright©2008 PR Newswire.
All rights reserved